Investing.comDoubao · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 18:04:32·⟳ 抓取 18:05:43 +1m11s·⚡ 决策 10-27 20:02:06 +1h56m·2.4 小时前
Aclaris公布ATI-052双抗1b期AD/哮喘阳性POC数据，同日5000万美元增发，盘前冲高翻绿
本条Investing.com文章为同日GlobeNewswire首发通稿的AI改写转载，bm25 97%命中3分钟前（10-27 11:57 UTC）已处理的同一具体催化，且转载稿信息更少（漏掉同日5000万美元增发）；已处理记录已完成多空研判：盘前冲高翻绿、利好实时派发，多空均无edge。无任何新增金额、指引修正、官方确认/否认或监管进展，按查重规则直接AVOID。
📄 原文Investing.com↗ 原文
Aclaris reports positive phase 1b trial results for ATI-052
WAYNE, Pa. - Aclaris Therapeutics Inc. (NASDAQ:ACRS) announced results from Phase 1b proof-of-concept trials of ATI-052…
不做 Aclaris Therapeutics（ACRS.US）
[契约校验:INVALID_SIDE] side: Input should be 'LONG' or 'SHORT'; entry: Field required; exit: Field required; size_tier: Field required 原理由:duplicate-stub
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
ATI-052的1b期阳性数据是14/16例极小样本POC且公司转向无数据的EoE，叠加同日5000万美元增发稀释；盘前已+26%冲高翻绿，利好被派发。本条仅为同一通稿的二手转载、无新增事实，多空均不做。
🔎 新鲜度:最早出现 2026-10-27 · 扩散 high · price-in 风险 high ↗
关键理由
- 数据虽阳性但样本极小、无统计效力，且公司放弃优先推进有数据的AD/哮喘、转向无数据的EoE，科学与监管层面均未产生决定性状态迁移
主要风险
- 同日5000万美元普通股及预出资权证增发带来直接摊薄，盘前+26%已翻绿至-3.7%（最低-19%），追多承接已被证伪，追空则面对20日已跌约30%后的反抽风险
先例如何影响了这次决策
对本次决策的影响:本条在跨源查重阶段即确认为同一具体催化的无新增事实转载，按早停规则不再重复检索外部先例；已处理记录的实时盘前派发事实（+26%翻绿至-3.7%）已足以否定剩余edge
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 1,176 ms
{"result": "search_processed_events:agent query=`aclaris ati-052 临床1b期 数据 | aclaris therapeutics ati-052 phase 1b results | acrs anti-tslp il-4rα bispecific atopic dermatitis asthma`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 69.8/72 小时、4883 条本臂决策(完整)，返回 1 条候选。\n• 10-27 11:57 UTC(北京 19:57) [bm25:97%] 不做 ACRS.US (wire - fetch_decision_experience 成功 stock_tools_inprocess · 3 ms
{
原文全文
展开原文 · 1,849 字
WAYNE, Pa. - Aclaris Therapeutics Inc. (NASDAQ:ACRS) announced results from Phase 1b proof-of-concept trials of ATI-052, its anti-TSLP/IL-4Rα bispecific antibody, in atopic dermatitis and asthma, according to a press release statement issued today.
The atopic dermatitis trial enrolled 14 patients with severe disease who received five weekly doses of 480 mg ATI-052 or placebo. Among per-protocol patients, 78% had severe disease at baseline. Patients treated with ATI-052 experienced a 45% placebo-adjusted mean change in Eczema Area and Severity Index score from baseline at day 57. At week 4, patients receiving ATI-052 showed a 40% placebo-adjusted mean improvement in itch scores.
The asthma trial evaluated a single 480 mg dose of ATI-052 in 16 patients with mild-to-moderate asthma. Patients experienced a 59% mean absolute reduction in fractional exhaled nitric oxide 15 days after administration compared to 15% in the placebo arm. Patients showed a placebo-adjusted mean improvement of 200 ml in forced expiratory volume in one second at day 15.
ATI-052 was well tolerated across both trials. Treatment-emergent adverse events were predominantly Grade 1, with no Grade 3 or 4 events reported. No adverse events led to study discontinuation, and no conjunctivitis was observed.
The company stated it intends to prioritize Phase 2b development of ATI-052 initially in eosinophilic esophagitis, planning to initiate a trial early next year.
ATI-052 is an investigational humanized bispecific antibody that simultaneously inhibits thymic stromal lymphopoietin and interleukin-4 receptor alpha. Aclaris holds exclusive worldwide rights to ATI-052, excluding Greater China.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Aclaris reports positive phase 1b trial results for ATI-052
The atopic dermatitis trial enrolled 14 patients with severe disease who received five weekly doses of 480 mg ATI-052 or placebo. Among per-protocol patients, 78% had severe disease at baseline. Patients treated with ATI-052 experienced a 45% placebo-adjusted mean change in Eczema Area and Severity Index score from baseline at day 57. At week 4, patients receiving ATI-052 showed a 40% placebo-adjusted mean improvement in itch scores.
The asthma trial evaluated a single 480 mg dose of ATI-052 in 16 patients with mild-to-moderate asthma. Patients experienced a 59% mean absolute reduction in fractional exhaled nitric oxide 15 days after administration compared to 15% in the placebo arm. Patients showed a placebo-adjusted mean improvement of 200 ml in forced expiratory volume in one second at day 15.
ATI-052 was well tolerated across both trials. Treatment-emergent adverse events were predominantly Grade 1, with no Grade 3 or 4 events reported. No adverse events led to study discontinuation, and no conjunctivitis was observed.
The company stated it intends to prioritize Phase 2b development of ATI-052 initially in eosinophilic esophagitis, planning to initiate a trial early next year.
ATI-052 is an investigational humanized bispecific antibody that simultaneously inhibits thymic stromal lymphopoietin and interleukin-4 receptor alpha. Aclaris holds exclusive worldwide rights to ATI-052, excluding Greater China.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Aclaris reports positive phase 1b trial results for ATI-052
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
f94641d578· 2026-10-27 20:02 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前